18889881171
Kalkine 0
countryflagUS

Artivion Inc

Healthcare US AORT

30.635USD
0.34(1.14%)

Last update at 2025-07-08T17:00:00Z

Day Range

30.3530.70
LowHigh

52 Week Range

16.4830.22
LowHigh

Fundamentals

  • Previous Close 30.29
  • Market Cap1215.68M
  • Volume92048
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA52.61M
  • Revenue TTM384.90M
  • Revenue Per Share TTM9.29
  • Gross Profit TTM 202.52M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.98400M -14.82700M -17.17400M 1.64M -6.39100M
Minority interest - - - - -
Net income -19.19200M -14.83400M -16.68200M 1.72M -3.80500M
Selling general administrative 157.44M 169.77M 141.14M 143.01M 140.57M
Selling and marketing expenses - - - - -
Gross profit 202.52M 197.51M 167.78M 183.01M 172.98M
Reconciled depreciation 22.44M 23.98M 20.71M 18.32M 18.09M
Ebit 3.24M -13.86300M 2.44M -1.78700M -8.69800M
Ebitda 25.68M 10.11M -0.47600M 16.53M 9.40M
Depreciation and amortization 22.44M 23.98M -2.91700M 18.32M 18.09M
Non operating income net other -2.96100M -6.05700M - - -
Operating income 3.24M -13.86300M 2.44M -1.78700M 9.31M
Other operating expenses 307.59M 306.64M 250.79M 259.18M 253.53M
Interest expense 18.22M 16.89M 16.70M 14.89M 15.79M
Tax provision 4.21M 0.00700M -0.49200M -0.07600M -3.55100M
Interest income 0.15M 0.08M 0.22M 0.74M 0.23M
Net interest income -18.07700M -16.80800M -16.48100M -14.14800M -15.56200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.21M 0.00700M -0.49200M -0.07600M -2.58600M
Total revenue 313.79M 298.84M 253.23M 276.22M 262.84M
Total operating expenses 196.32M 205.32M 165.34M 165.97M 163.67M
Cost of revenue 111.27M 101.32M 85.44M 93.21M 89.86M
Total other income expense net -18.22400M -0.96400M -19.61500M 3.43M -0.14100M
Discontinued operations - - - - -
Net income from continuing ops -19.19200M -14.83400M -16.68200M 1.72M -2.84000M
Net income applicable to common shares -19.19200M -14.83400M -16.57100M 1.71M -2.81300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 792.40M 762.80M 793.05M 789.40M 605.65M
Intangible assets 172.23M 182.65M 201.50M 227.06M 157.73M
Earning assets - - - - -
Other current assets 65.61M 17.55M 57.61M 50.84M 44.16M
Total liab 510.62M 478.47M 492.32M 460.69M 319.96M
Total stockholder equity 281.78M 284.33M 300.73M 328.71M 285.70M
Deferred long term liab - 29.97M 34.75M - -
Other current liab 35.28M 7.74M 1.08M 19.18M 1.81M
Common stock 0.43M 0.42M 0.41M 0.40M 0.39M
Capital stock 0.43M 0.42M 0.41M 0.40M 0.39M
Retained earnings -47.90700M -17.21700M 1.98M 20.02M 36.70M
Other liab - 77.39M 90.64M 90.42M 36.86M
Good will 247.34M 243.63M 250.00M 260.06M 186.70M
Other assets - 8.65M 10.62M 16.05M 19.69M
Cash 58.94M 39.35M 55.01M 61.96M 34.29M
Cash and equivalents - - - - -
Total current liabilities 57.86M 49.67M 44.95M 60.47M 45.20M
Current deferred revenue 3.84M 24.50M 28.17M 24.09M 26.34M
Net debt 299.40M 317.48M 307.03M 255.42M 210.86M
Short term debt 5.43M 5.43M 5.31M 7.57M 7.25M
Short long term debt 1.45M 1.61M 1.63M 1.20M 1.16M
Short long term debt total 358.34M 356.83M 362.04M 317.37M 245.15M
Other stockholder equity 341.27M 322.74M 308.23M 301.54M 257.19M
Property plant equipment - 38.67M 83.23M 51.65M 54.14M
Total current assets 280.67M 247.33M 247.70M 234.59M 187.39M
Long term investments - - - - -
Net tangible assets - -141.94900M -150.76800M -158.40500M -58.73500M
Short term investments - - - - -
Net receivables 74.14M 69.58M 58.10M 48.75M 55.86M
Long term debt 305.53M 306.50M 307.49M 290.47M 214.57M
Inventory 81.98M 74.48M 76.97M 73.04M 53.07M
Accounts payable 13.32M 12.00M 10.39M 9.62M 9.80M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -12.01000M -21.60900M -9.88700M 6.74M -8.58900M
Additional paid in capital - - - - -
Common stock total equity - 0.42M 0.41M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -17.21700M 1.98M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8.89M 7.34M 8.27M 14.60M 14.21M
Deferred long term asset charges - - - - -
Non current assets total 511.73M 515.46M 545.36M 554.82M 418.26M
Capital lease obligations 51.36M 48.72M 52.92M 25.71M 29.42M
Long term debt total - 306.50M 307.49M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -10.71500M 5.66M -73.12800M -23.94300M -6.71500M
Change to liabilities -1.95800M -1.89300M -9.15700M 0.25M -8.87000M
Total cashflows from investing activities -10.71500M 5.66M -73.12800M -23.94300M -6.71500M
Net borrowings -2.75300M -3.08500M 94.65M -2.78000M -2.79000M
Total cash from financing activities -1.63900M -12.22300M 93.61M -1.49300M -2.56200M
Change to operating activities -2.23400M -1.40400M -2.72000M -6.17700M -2.40700M
Net income -19.19200M -14.83400M -16.68200M 1.72M -2.84000M
Change in cash -15.65900M -6.94800M 27.66M -7.94200M 1.48M
Begin period cash flow 55.01M 61.96M 34.29M 42.24M 40.75M
End period cash flow 39.35M 55.01M 61.96M 34.29M 42.24M
Total cash from operating activities -5.15300M -2.58500M 12.37M 15.83M 9.88M
Issuance of capital stock - - - - -
Depreciation 22.44M 23.98M 20.71M 18.32M 18.09M
Other cashflows from investing activities -1.69900M -0.24900M -1.68100M -0.87100M -0.92900M
Dividends paid - - - - -
Change to inventory -8.40400M -18.37500M -24.75700M -8.12500M 2.38M
Change to account receivables -13.34000M -11.56000M 9.94M -3.38400M -5.91000M
Sale purchase of stock -1.79500M -1.91400M -1.99500M -2.74300M -2.10000M
Other cashflows from financing activities -0.45900M -7.22400M 130.95M 4.03M 2.33M
Change to netincome 5.73M 21.50M 33.34M 9.37M 4.20M
Capital expenditures 10.71M 13.09M 7.33M 8.07M 5.79M
Change receivables -13.34000M -11.56000M - - -
Cash flows other operating 9.57M 11.90M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -17.50700M -9.14800M - - -
Change in working capital -25.93600M -33.23200M -26.69600M -19.38300M -10.01200M
Stock based compensation 12.34M 10.71M 6.91M 8.80M 6.33M
Other non cash items 6.91M 15.26M 23.84M 8.68M 2.80M
Free cash flow -15.86800M -15.67600M 5.04M 7.75M 4.09M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AORT
Artivion Inc		 0.34 1.14% 30.64 - 185.19 3.16 4.08 4.03 24.61
ABT
Abbott Laboratories		 0.33 0.25% 134.03 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -1.835 0.47% 390.68 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.76 0.87% 88.43 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.685 1.62% 102.14 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Artivion Inc

1655 Roberts Boulevard N.W., Kennesaw, GA, United States, 30144

Key Executives

Name Title Year Born
Mr. James Patrick Mackin Chairman, Pres & CEO 1967
Mr. David Ashley Lee CPA, CPA Exec. VP, COO & CFO 1965
Ms. Jean F. Holloway Esq. Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1957
Mr. John E. Davis Sr. VP of Global Sales & Marketing 1965
Dr. Marshall S. Stanton M.D. Sr. VP of Clinical Research & Chief Medical Officer 1957
Ms. Amy D. Horton CPA, CPA VP & Chief Accounting Officer 1970
Mr. Matthew A. Getz VP of HR 1969
Mr. Dennis B. Maier Sr. VP of Operations 1974
Joshua Wells Sr. Director of Bus. Devel. NA
Mr. James Patrick Mackin Chairman, President & CEO 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.